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When to stop or decrease the dose of the drug is a crucial problem.
Additionally, whether pairing of aspirin and thienopyridine is best for
any patient is unknown because how to assess the effects of the antico-
agulants is unknown.
How to decide the optimum duration and how to choose the opti-
mum antithrombotic drugs remain uncertain because the optimum
assessment method for antithrombotic drugs remains unknown.
Since 2012, I have published many cases of pulmonary vein
thromboses using 64-slice multidetector computed tomography
(64-MDCT) [3–10]. In 2014, I reported that 35 (61%) of 57 elderlyThe optimum duration of dual antiplatelet treatment (DAPT) with a
thienopyridine drug (clopidogrel or prasugrel) and aspirin to prevent
stent thrombosis after coronary drug-eluting stent placement remains
uncertain. Some studies report the merits and demerits of extended
treatment.
Continued thienopyridine treatment beyond one year after place-
ment of a drug-eluting stent, compared with aspirin therapy alone,
reduced the rates of stent thrombosis, myocardial infarction and
cerebrovascular events. However, the rate of death from any cause
was increased with continued thienopyridine treatment [1,2]. Addi-
tionally, a signiﬁcant increase in the risk of cancer-related death in
patients receiving continuous DAPT, compared with aspirin therapy
alone, was reported [1], indicating that we require a method to esti-
mate the effects of antiplatelets drugs.
Palmerini et al. reported that patients treated with DAPT for longer
than one year had a higher risk of mortality but a lower risk of myocar-
dial infarction and stent thrombosis compared with patients treated
with DAPT for six months or shorter and for one year. Patients treated
with one-yearDAPThad similar rates ofmortality,myocardial infarction
and stent thrombosis but higher rates of major bleeding comparedwith
patients treated for six months or less [2].0205, Japan. Tel.: +81 959 86
.
and Ltd. This is an open access articleMore than a one-year treatment of DAPT results in injurious effects.
patients with chest pain had pulmonary vein thromboses [4]. I re-
ported that we could assess the resistance of antiplatelet therapies
using 64-MDCT [9].
In this manuscript, a 64-MDCT scan showed that a 68-year-old male
had thrombi in the left lower pulmonary vein (LLPV) and the branches
of the LLPV (Fig. 1A to E). After three months of dabigatran therapy, the
thrombus was dissolved almost entirely (Fig. 1F to J). In Fig. 1H, the red
arrow indicates a newly appeared enhanced pulmonary vein that was
not illustrated in Fig. 1C, indicating that dabigatran restored a collapsed
pulmonary vein by dissolving the thrombus.
Because 64-MDCT can assess even small arteries accurately, it
could be utilized to assess pulmonary vein thrombus. As I reported,
some patients with chest pain had pulmonary vein thrombi [3–10];
we can utilize a 64-MDCT scan to decide the optimum duration of
DAPT if the patients have pulmonary vein thrombi and DAPT can dis-
solve pulmonary vein thrombi. Even if DAPT does not dissolve pul-
monary vein thrombi, DAPT may be useful if it can inhibit the growth
of pulmonary vein thrombi or the production of microclots. Moreover,
we can change antithrombotic drugs if DAPT has no ability to dissolve
a pulmonary vein thrombus. To choose optimum antithrombotic
drugs, 64-MDCT may be useful. More studies are required to use
64-MDCT for this purpose.
It may be possible to decide the optimum duration of DAPT, as
assessed by the change of pulmonary vein thrombi using 64-MDCT.
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Fig. 1. An axial image demonstrating A: A thrombus in the left lower pulmonary vein (LLPV) as a defect of contrast enhancements (white arrow). B: The thrombus becomes smaller,
indicating that one branch of the LLPV was occluded (white arrow), and the occluded small pulmonary vein was illustrated (green arrow). C to E: The occluded branch was illustrated
(white arrow), and the occluded small pulmonary veins were illustrated (green arrows). After three months of dabigatran therapy, an axial image demonstrating F: the thrombus was
dissolved. Something appeared to be left (white arrow), whichmay be the ﬁbrin network of the thrombus. G: a new enhanced small pulmonary vein appeared (green arrows), indicating
that dabigatran dissolved the thrombi in the small pulmonary veins. (C, H) H: A new enhanced small pulmonary vein seemed to appear (red arrow), and there seemed to be a collapsed
pulmonary vein in panel C that was not clearly illustrated. A branch of LLPV without a thrombus was illustrated in panels E and J (white arrowhead).
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